KBW personal page - To The Moon

KBW

KBW

No personal profile

28Follow

5Followers

1Topic

0Badge

02-17

huat huat huat dragon year

2023-11-06

up

@TigerEvents:Join Tiger's Halloween Fun! Win Big!

2022-11-17

Thanksgiving Come, have a look.

@TigerEvents:[Thanksgiving] Say thank you to your friends

2022-04-29

Yeah

Why Teladoc Health's Latest Earnings Call Was So Disappointing

2021-07-04

Good, stock

2021-06-17

$Gaucho Group Holdings, Inc.(VINO)$wah

2021-06-15

$RAPT Therapeutics, Inc.(RAPT)$how to know this kind of share

2021-06-13

$Kanzhun Limited(BZ)$nice

2021-06-12

$Huntington Bancshares Inc(HBANM)$good

2021-06-11

$Orphazyme A/S(ORPH)$wah

2021-06-09

$Clover Health Corp(CLOV)$good

2021-06-06

$Senseonics(SENS)$good

2021-06-04

$Adamis Pharmaceuticals(ADMP)$good

2021-06-03

Great

2021-06-01

$Orbital Energy Group(OEG)$good

2021-05-30

$eMagin(EMAN)$good

2021-05-29

$Vertex(VTNR)$good

2021-05-28

$Vertex(VTNR)$strong

2021-05-27

$LIZHI Inc(LIZI)$wow

2021-05-26

I see

上海消保委约谈美团、拼多多，指出多项突出问题

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3576471374930041","uuid":"3576471374930041","gmtCreate":1613378312425,"gmtModify":1613568657571,"name":"KBW","pinyin":"kbw","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":28,"tweetSize":64,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.15%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":274865270403192,"gmtCreate":1708143562466,"gmtModify":1708143567965,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"huat huat huat dragon year","listText":"huat huat huat dragon year","text":"huat huat huat dragon year","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/274865270403192","isVote":1,"tweetType":1,"viewCount":422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":238365317427360,"gmtCreate":1699230346339,"gmtModify":1699230349448,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"up","listText":"up","text":"up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/238365317427360","repostId":"234641357262864","repostType":1,"repost":{"id":234641357262864,"gmtCreate":1698311576543,"gmtModify":1698655637693,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667667103859","idStr":"3527667667103859"},"themes":[],"title":"Join Tiger's Halloween Fun! Win Big!","htmlText":"Hey there, spooky squad! 🎃Halloween is coming, and it's time for some fang-tastic fun with our new game - Trick Or Trade! Get ready for some fun, and earn points to win a USD 100 stock voucher and AAPL stock!*In this thrilling game, you'll have just 60 seconds to fend off a gang of mischievous Halloween spirits. It's your job to give them a fright and chase them away with a tap – the more, the merrier!Now, here's the twist: each ghostly friend will require different taps and will reward you with various points.Airy the Apparition - Just one tap, and poof, they vanish. Spooktacularly easy!Bubbles the Water Pixie - Disappears with zero taps - A true magic trick!Rocky the Earth Spirit - You'll need to tap twice to send it packing. He's grounded, you see.Flicker the Embergeist - Another one-ta","listText":"Hey there, spooky squad! 🎃Halloween is coming, and it's time for some fang-tastic fun with our new game - Trick Or Trade! Get ready for some fun, and earn points to win a USD 100 stock voucher and AAPL stock!*In this thrilling game, you'll have just 60 seconds to fend off a gang of mischievous Halloween spirits. It's your job to give them a fright and chase them away with a tap – the more, the merrier!Now, here's the twist: each ghostly friend will require different taps and will reward you with various points.Airy the Apparition - Just one tap, and poof, they vanish. Spooktacularly easy!Bubbles the Water Pixie - Disappears with zero taps - A true magic trick!Rocky the Earth Spirit - You'll need to tap twice to send it packing. He's grounded, you see.Flicker the Embergeist - Another one-ta","text":"Hey there, spooky squad! 🎃Halloween is coming, and it's time for some fang-tastic fun with our new game - Trick Or Trade! Get ready for some fun, and earn points to win a USD 100 stock voucher and AAPL stock!*In this thrilling game, you'll have just 60 seconds to fend off a gang of mischievous Halloween spirits. It's your job to give them a fright and chase them away with a tap – the more, the merrier!Now, here's the twist: each ghostly friend will require different taps and will reward you with various points.Airy the Apparition - Just one tap, and poof, they vanish. Spooktacularly easy!Bubbles the Water Pixie - Disappears with zero taps - A true magic trick!Rocky the Earth Spirit - You'll need to tap twice to send it packing. He's grounded, you see.Flicker the Embergeist - Another one-ta","images":[{"img":"https://community-static.tradeup.com/news/ad478b709732d53302c395a52fa1c8e1","width":"1200","height":"630"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/234641357262864","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":488,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9963217685,"gmtCreate":1668691707447,"gmtModify":1676538097730,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"Thanksgiving Come, have a look.","listText":"Thanksgiving Come, have a look.","text":"Thanksgiving Come, have a look.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9963217685","repostId":"9963622384","repostType":1,"repost":{"id":9963622384,"gmtCreate":1668668460748,"gmtModify":1676538094204,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667667103859","idStr":"3527667667103859"},"themes":[],"title":"[Thanksgiving] Say thank you to your friends","htmlText":"Hi Tigers,Thanksgiving is just around the corner! We have prepared Tiger Coins and gifts for you to participate in our Thanksgiving event.Thanksgiving Day is an annual national holiday in the United States and Singapore that celebrates the harvest and other blessings of the previous year. In addition, people express their gratitude to those who helped them over the past year.In the past year, who gave you the biggest help? We would like to invite you to say thank you to those who have helped you in the past year.💡How to participate Like and Repost the campaign post.","listText":"Hi Tigers,Thanksgiving is just around the corner! We have prepared Tiger Coins and gifts for you to participate in our Thanksgiving event.Thanksgiving Day is an annual national holiday in the United States and Singapore that celebrates the harvest and other blessings of the previous year. In addition, people express their gratitude to those who helped them over the past year.In the past year, who gave you the biggest help? We would like to invite you to say thank you to those who have helped you in the past year.💡How to participate Like and Repost the campaign post.","text":"Hi Tigers,Thanksgiving is just around the corner! We have prepared Tiger Coins and gifts for you to participate in our Thanksgiving event.Thanksgiving Day is an annual national holiday in the United States and Singapore that celebrates the harvest and other blessings of the previous year. In addition, people express their gratitude to those who helped them over the past year.In the past year, who gave you the biggest help? We would like to invite you to say thank you to those who have helped you in the past year.💡How to participate Like and Repost the campaign post.","images":[{"img":"https://community-static.tradeup.com/news/35d6ad50d602c819c196296c6d5b4f4f","width":"1125","height":"360"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9963622384","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9060537946,"gmtCreate":1651163945201,"gmtModify":1676534862230,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9060537946","repostId":"2230408224","repostType":4,"repost":{"id":"2230408224","pubTimestamp":1651157900,"share":"https://ttm.financial/m/news/2230408224?lang=&edition=fundamental","pubTime":"2022-04-28 22:58","market":"us","language":"en","title":"Why Teladoc Health's Latest Earnings Call Was So Disappointing","url":"https://stock-news.laohu8.com/highlight/detail?id=2230408224","media":"Motley Fool","summary":"An enormous write-down on its chronic-care business is just part of the problem.","content":"<html><head></head><body><p>Quick: Somebody call a virtual doctor! The stock market just pushed America&#39;s leading telehealth business down a flight of stairs.</p><p>Shares of <b>Teladoc Health</b> fell hard after U.S. stock markets closed on Wednesday in response to a dismal first-quarter earnings call. The company was able to report total revenue that soared 25% year over year, but the market is responding to signs of trouble that aren&#39;t apparent until you look past the headline numbers.</p><p>Here&#39;s why investment bank analysts quickly lined up to downgrade the already embattled telehealth stock.</p><h2>A chronic disaster</h2><p>Using smartphones to connect patients with doctors is a minor challenge that at least a dozen of Teladoc&#39;s competitors can handle. With this fear of commoditization in mind, Teladoc Health boldly acquired a chronic-care management business called Livongo Health for $18.5 billion in 2020.</p><p>Just before the acquisition, Livongo was growing by leaps and bounds. On Sept. 30, 2020, Livongo for Diabetes had 442,000 members, which was 113% more than it had a year earlier.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F676616%2Fchronic-care-membership-following-the-acquisition-of-livongo.png&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"432\" width=\"100%\" height=\"auto\"/><span>Data source: Teladoc Health. Chart by author.</span></p><p>Livongo had already begun expanding from its flagship diabetes service to blood pressure management and weight loss at the time of the acquisition. Despite having a lot more resources to work with than Livongo did, Teladoc hasn&#39;t been able to repeat Livongo&#39;s success. In fact, chronic-care membership has slowed down so much that the company had to record a whopping $6.6 billion impairment charge related to the Livongo acquisition.</p><h2>BetterHelp needs help</h2><p>Teladoc Health&#39;s chronic-care numbers have been disappointing for over a year. But BetterHelp, its mental health segment, was until recently making big gains. Unfortunately, the company is losing ground to well-funded competitors that keep entering the market.</p><p>For example, <b>Talkspace</b> went public in a $1.4 billion deal with a special purpose acquisition company (SPAC) last year.</p><p>When reporting first-quarter results, Teladoc Health walked back the forward-looking guidance it provided three months earlier. Instead of revenue rising to a range between $2.55 billion and $2.65 billion, the company told investors to expect between $2.4 billion and $2.5 billion in top-line sales. According to management, investing in heavy advertising for BetterHelp has been delivering lower returns than it used to. Specifically, the company complained about increasing competition for keywords associated with online therapy.</p><h2>More trouble ahead</h2><p>Teladoc Health is the largest independent telehealth business in America, but it&#39;s competing with some deep-pocketed giants of the healthcare-benefits management industry that want their members to see the physicians they employ.</p><p>For example, <b>CVS Health</b> acquired Aetna a few years ago, and it also operates MinuteClinics in many of its pharmacies that also offer virtual visits. CVS Health would never say so in so many words, but it has a lot to gain when Aetna members visit physicians employed by a CVS MinuteClinic versus Teladoc Health.</p><p>Cash flow generated by CVS Health&#39;s highly integrated operations reached a whopping $18.3 billion last year, and the company expects between $12.5 billion and $13 billion this year. In stark contrast, cash from Teladoc Health&#39;s operations came in below $200 million last year and slid back into negative territory in the first quarter of 2022.</p><p>Teladoc Health may be the largest pure-play business in the telehealth industry, but we still don&#39;t know if it can compete with giant healthcare benefits managers and a slew of smaller upstarts at the same time. It&#39;s probably a good idea to watch the company&#39;s story play out from a safe distance until we see signs it can compete in a rapidly shifting market for telehealth services.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Teladoc Health's Latest Earnings Call Was So Disappointing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Teladoc Health's Latest Earnings Call Was So Disappointing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-28 22:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/28/why-teladoc-healths-latest-earnings-call-was-so-di/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quick: Somebody call a virtual doctor! The stock market just pushed America's leading telehealth business down a flight of stairs.Shares of Teladoc Health fell hard after U.S. stock markets closed on ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/28/why-teladoc-healths-latest-earnings-call-was-so-di/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/04/28/why-teladoc-healths-latest-earnings-call-was-so-di/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2230408224","content_text":"Quick: Somebody call a virtual doctor! The stock market just pushed America's leading telehealth business down a flight of stairs.Shares of Teladoc Health fell hard after U.S. stock markets closed on Wednesday in response to a dismal first-quarter earnings call. The company was able to report total revenue that soared 25% year over year, but the market is responding to signs of trouble that aren't apparent until you look past the headline numbers.Here's why investment bank analysts quickly lined up to downgrade the already embattled telehealth stock.A chronic disasterUsing smartphones to connect patients with doctors is a minor challenge that at least a dozen of Teladoc's competitors can handle. With this fear of commoditization in mind, Teladoc Health boldly acquired a chronic-care management business called Livongo Health for $18.5 billion in 2020.Just before the acquisition, Livongo was growing by leaps and bounds. On Sept. 30, 2020, Livongo for Diabetes had 442,000 members, which was 113% more than it had a year earlier.Data source: Teladoc Health. Chart by author.Livongo had already begun expanding from its flagship diabetes service to blood pressure management and weight loss at the time of the acquisition. Despite having a lot more resources to work with than Livongo did, Teladoc hasn't been able to repeat Livongo's success. In fact, chronic-care membership has slowed down so much that the company had to record a whopping $6.6 billion impairment charge related to the Livongo acquisition.BetterHelp needs helpTeladoc Health's chronic-care numbers have been disappointing for over a year. But BetterHelp, its mental health segment, was until recently making big gains. Unfortunately, the company is losing ground to well-funded competitors that keep entering the market.For example, Talkspace went public in a $1.4 billion deal with a special purpose acquisition company (SPAC) last year.When reporting first-quarter results, Teladoc Health walked back the forward-looking guidance it provided three months earlier. Instead of revenue rising to a range between $2.55 billion and $2.65 billion, the company told investors to expect between $2.4 billion and $2.5 billion in top-line sales. According to management, investing in heavy advertising for BetterHelp has been delivering lower returns than it used to. Specifically, the company complained about increasing competition for keywords associated with online therapy.More trouble aheadTeladoc Health is the largest independent telehealth business in America, but it's competing with some deep-pocketed giants of the healthcare-benefits management industry that want their members to see the physicians they employ.For example, CVS Health acquired Aetna a few years ago, and it also operates MinuteClinics in many of its pharmacies that also offer virtual visits. CVS Health would never say so in so many words, but it has a lot to gain when Aetna members visit physicians employed by a CVS MinuteClinic versus Teladoc Health.Cash flow generated by CVS Health's highly integrated operations reached a whopping $18.3 billion last year, and the company expects between $12.5 billion and $13 billion this year. In stark contrast, cash from Teladoc Health's operations came in below $200 million last year and slid back into negative territory in the first quarter of 2022.Teladoc Health may be the largest pure-play business in the telehealth industry, but we still don't know if it can compete with giant healthcare benefits managers and a slew of smaller upstarts at the same time. It's probably a good idea to watch the company's story play out from a safe distance until we see signs it can compete in a rapidly shifting market for telehealth services.","news_type":1},"isVote":1,"tweetType":1,"viewCount":671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155362629,"gmtCreate":1625377264561,"gmtModify":1703741039178,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"Good, stock","listText":"Good, stock","text":"Good, stock","images":[{"img":"https://static.tigerbbs.com/05ccb4bffb4d3d16d7c15e2c9e9324bb","width":"1080","height":"2766"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/155362629","isVote":1,"tweetType":1,"viewCount":923,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":163755691,"gmtCreate":1623894465013,"gmtModify":1703822798452,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VINO\">$Gaucho Group Holdings, Inc.(VINO)$</a>wah","listText":"<a href=\"https://laohu8.com/S/VINO\">$Gaucho Group Holdings, Inc.(VINO)$</a>wah","text":"$Gaucho Group Holdings, Inc.(VINO)$wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163755691","isVote":1,"tweetType":1,"viewCount":992,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184463580,"gmtCreate":1623721931940,"gmtModify":1704209545331,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RAPT\">$RAPT Therapeutics, Inc.(RAPT)$</a>how to know this kind of share","listText":"<a href=\"https://laohu8.com/S/RAPT\">$RAPT Therapeutics, Inc.(RAPT)$</a>how to know this kind of share","text":"$RAPT Therapeutics, Inc.(RAPT)$how to know this kind of share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/184463580","isVote":1,"tweetType":1,"viewCount":934,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182651928,"gmtCreate":1623571076664,"gmtModify":1704206440636,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BZ\">$Kanzhun Limited(BZ)$</a>nice","listText":"<a href=\"https://laohu8.com/S/BZ\">$Kanzhun Limited(BZ)$</a>nice","text":"$Kanzhun Limited(BZ)$nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182651928","isVote":1,"tweetType":1,"viewCount":724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188797666,"gmtCreate":1623461334255,"gmtModify":1704204205818,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HBANM\">$Huntington Bancshares Inc(HBANM)$</a>good","listText":"<a href=\"https://laohu8.com/S/HBANM\">$Huntington Bancshares Inc(HBANM)$</a>good","text":"$Huntington Bancshares Inc(HBANM)$good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188797666","isVote":1,"tweetType":1,"viewCount":967,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":181327655,"gmtCreate":1623375155377,"gmtModify":1704201964018,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>wah","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>wah","text":"$Orphazyme A/S(ORPH)$wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181327655","isVote":1,"tweetType":1,"viewCount":908,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3576807236070433","authorId":"3576807236070433","name":"_GOD_","avatar":"https://static.tigerbbs.com/a7926464e49b85685a50f1e80f5ff8cd","crmLevel":3,"crmLevelSwitch":1,"authorIdStr":"3576807236070433","idStr":"3576807236070433"},"content":"Wah! I made $600,000!! And sold all! I am The GOD OF STOCKS","text":"Wah! I made $600,000!! And sold all! I am The GOD OF STOCKS","html":"Wah! I made $600,000!! And sold all! I am The GOD OF STOCKS"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":180628529,"gmtCreate":1623202533261,"gmtModify":1704198232242,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>good","listText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>good","text":"$Clover Health Corp(CLOV)$good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180628529","isVote":1,"tweetType":1,"viewCount":764,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":115693317,"gmtCreate":1622981599039,"gmtModify":1704194042485,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>good","listText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>good","text":"$Senseonics(SENS)$good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/115693317","isVote":1,"tweetType":1,"viewCount":604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":116891955,"gmtCreate":1622785622677,"gmtModify":1704191170442,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ADMP\">$Adamis Pharmaceuticals(ADMP)$</a>good","listText":"<a href=\"https://laohu8.com/S/ADMP\">$Adamis Pharmaceuticals(ADMP)$</a>good","text":"$Adamis Pharmaceuticals(ADMP)$good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/116891955","isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111273738,"gmtCreate":1622684475624,"gmtModify":1704188854126,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/111273738","isVote":1,"tweetType":1,"viewCount":353,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119404826,"gmtCreate":1622557359765,"gmtModify":1704186311087,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OEG\">$Orbital Energy Group(OEG)$</a>good","listText":"<a href=\"https://laohu8.com/S/OEG\">$Orbital Energy Group(OEG)$</a>good","text":"$Orbital Energy Group(OEG)$good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119404826","isVote":1,"tweetType":1,"viewCount":329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":137683465,"gmtCreate":1622343178557,"gmtModify":1704183224006,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EMAN\">$eMagin(EMAN)$</a>good","listText":"<a href=\"https://laohu8.com/S/EMAN\">$eMagin(EMAN)$</a>good","text":"$eMagin(EMAN)$good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/137683465","isVote":1,"tweetType":1,"viewCount":420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":137990875,"gmtCreate":1622278653597,"gmtModify":1704182646427,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VTNR\">$Vertex(VTNR)$</a>good","listText":"<a href=\"https://laohu8.com/S/VTNR\">$Vertex(VTNR)$</a>good","text":"$Vertex(VTNR)$good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/137990875","isVote":1,"tweetType":1,"viewCount":358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":135423836,"gmtCreate":1622177613425,"gmtModify":1704180958983,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VTNR\">$Vertex(VTNR)$</a>strong","listText":"<a href=\"https://laohu8.com/S/VTNR\">$Vertex(VTNR)$</a>strong","text":"$Vertex(VTNR)$strong","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/135423836","isVote":1,"tweetType":1,"viewCount":387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":132777405,"gmtCreate":1622119767107,"gmtModify":1704179799300,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LIZI\">$LIZHI Inc(LIZI)$</a>wow","listText":"<a href=\"https://laohu8.com/S/LIZI\">$LIZHI Inc(LIZI)$</a>wow","text":"$LIZHI Inc(LIZI)$wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132777405","isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136196336,"gmtCreate":1621997736425,"gmtModify":1704365759224,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576471374930041","idStr":"3576471374930041"},"themes":[],"htmlText":"I see","listText":"I see","text":"I see","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/136196336","repostId":"1126498558","repostType":2,"repost":{"id":"1126498558","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620646604,"share":"https://ttm.financial/m/news/1126498558?lang=&edition=fundamental","pubTime":"2021-05-10 19:36","market":"us","language":"zh","title":"上海消保委约谈美团、拼多多，指出多项突出问题","url":"https://stock-news.laohu8.com/highlight/detail?id=1126498558","media":"老虎资讯综合","summary":"据上海市消费者权益保护委员会微信公众号10日消息，“五一”前后，上海消费市场投诉总体平稳，但与此同时，线上平台类消费争议相对集中多发。为此，上海市消保委在今天（10日）下午，约谈了美团，指出了美团在消","content":"<p>据上海市消费者权益保护委员会微信公众号10日消息，“五一”前后，上海消费市场投诉总体平稳，但与此同时，线上平台类消费争议相对集中多发。为此，<b>上海市消保委在今天（10日）下午，约谈了<a href=\"https://laohu8.com/S/03690\">美团</a>，指出了美团在消费者权益保护方面存在的突出问题。</b></p><p>美团表示，公司将根据上海市消保委的要求，对其相关的业务进行自查与整肃，并将于近日向消保委递交整改报告。</p><p>另外，<b>上海市消保委在今天（10日）下午，约谈了<a href=\"https://laohu8.com/S/PDD\">拼多多</a>，指出了拼多多在消费者权益保护方面存在的突出问题。</b>拼多多的主要问题：一是商品质量问题；二是假冒侵权问题；三是强制取消订单；四是虚假发货问题；五是售后服务问题；六是砍价拉新问题。</p><p>截至发稿，拼多多盘前短线走低，跌3.77%。</p><p><img src=\"https://static.tigerbbs.com/4c43b05e291772b8b1d3bb0c857abe7d\" tg-width=\"600\" tg-height=\"373\" referrerpolicy=\"no-referrer\"></p><p>上海市消保委表示：近年来，各类互联网平台将消费需求与商品和服务的提供进行撮合、匹配，很好地解决了交易过程中的信息不对称，既有效降低了消费者的决策成本，又大大提高了消费便捷程度，使得网络购物、旅游出行、本地生活等平台迅速崛起并发展壮大。</p><p>然而，日趋激烈的同质化平台间的竞争和互联网经济对流量的不断争夺导致不少平台唯“流量至上”、独“流量为王”。例如，有的平台为了流量，放任虚假广告和假冒伪劣商品充斥平台；有的平台为了流量，对入驻商户的资质审核和质量管控形同虚设；有的平台为了流量，对刷单炒信、虚假发货等问题查处不力；还有的平台为了流量，存在强制商家进行平台“二选一”的行为。</p><p>市消保委认为，平台只顾眼前利益的做法无异于“竭泽而渔”，呼吁相关平台企业彻底扭转唯“流量至上”的错误思维，正视消费者合法权益，主动承担社会责任，强化平台治理，用诚信合规经营创造更大价值。</p><p>接下来，上海市消保委还将对存在相关问题的其他平台进行约谈。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>上海消保委约谈美团、拼多多，指出多项突出问题</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n上海消保委约谈美团、拼多多，指出多项突出问题\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-05-10 19:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>据上海市消费者权益保护委员会微信公众号10日消息，“五一”前后，上海消费市场投诉总体平稳，但与此同时，线上平台类消费争议相对集中多发。为此，<b>上海市消保委在今天（10日）下午，约谈了<a href=\"https://laohu8.com/S/03690\">美团</a>，指出了美团在消费者权益保护方面存在的突出问题。</b></p><p>美团表示，公司将根据上海市消保委的要求，对其相关的业务进行自查与整肃，并将于近日向消保委递交整改报告。</p><p>另外，<b>上海市消保委在今天（10日）下午，约谈了<a href=\"https://laohu8.com/S/PDD\">拼多多</a>，指出了拼多多在消费者权益保护方面存在的突出问题。</b>拼多多的主要问题：一是商品质量问题；二是假冒侵权问题；三是强制取消订单；四是虚假发货问题；五是售后服务问题；六是砍价拉新问题。</p><p>截至发稿，拼多多盘前短线走低，跌3.77%。</p><p><img src=\"https://static.tigerbbs.com/4c43b05e291772b8b1d3bb0c857abe7d\" tg-width=\"600\" tg-height=\"373\" referrerpolicy=\"no-referrer\"></p><p>上海市消保委表示：近年来，各类互联网平台将消费需求与商品和服务的提供进行撮合、匹配，很好地解决了交易过程中的信息不对称，既有效降低了消费者的决策成本，又大大提高了消费便捷程度，使得网络购物、旅游出行、本地生活等平台迅速崛起并发展壮大。</p><p>然而，日趋激烈的同质化平台间的竞争和互联网经济对流量的不断争夺导致不少平台唯“流量至上”、独“流量为王”。例如，有的平台为了流量，放任虚假广告和假冒伪劣商品充斥平台；有的平台为了流量，对入驻商户的资质审核和质量管控形同虚设；有的平台为了流量，对刷单炒信、虚假发货等问题查处不力；还有的平台为了流量，存在强制商家进行平台“二选一”的行为。</p><p>市消保委认为，平台只顾眼前利益的做法无异于“竭泽而渔”，呼吁相关平台企业彻底扭转唯“流量至上”的错误思维，正视消费者合法权益，主动承担社会责任，强化平台治理，用诚信合规经营创造更大价值。</p><p>接下来，上海市消保委还将对存在相关问题的其他平台进行约谈。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f684c21951797edd0d31e494569f7907","relate_stocks":{"PDD":"拼多多","03690":"美团-W"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126498558","content_text":"据上海市消费者权益保护委员会微信公众号10日消息，“五一”前后，上海消费市场投诉总体平稳，但与此同时，线上平台类消费争议相对集中多发。为此，上海市消保委在今天（10日）下午，约谈了美团，指出了美团在消费者权益保护方面存在的突出问题。美团表示，公司将根据上海市消保委的要求，对其相关的业务进行自查与整肃，并将于近日向消保委递交整改报告。另外，上海市消保委在今天（10日）下午，约谈了拼多多，指出了拼多多在消费者权益保护方面存在的突出问题。拼多多的主要问题：一是商品质量问题；二是假冒侵权问题；三是强制取消订单；四是虚假发货问题；五是售后服务问题；六是砍价拉新问题。截至发稿，拼多多盘前短线走低，跌3.77%。上海市消保委表示：近年来，各类互联网平台将消费需求与商品和服务的提供进行撮合、匹配，很好地解决了交易过程中的信息不对称，既有效降低了消费者的决策成本，又大大提高了消费便捷程度，使得网络购物、旅游出行、本地生活等平台迅速崛起并发展壮大。然而，日趋激烈的同质化平台间的竞争和互联网经济对流量的不断争夺导致不少平台唯“流量至上”、独“流量为王”。例如，有的平台为了流量，放任虚假广告和假冒伪劣商品充斥平台；有的平台为了流量，对入驻商户的资质审核和质量管控形同虚设；有的平台为了流量，对刷单炒信、虚假发货等问题查处不力；还有的平台为了流量，存在强制商家进行平台“二选一”的行为。市消保委认为，平台只顾眼前利益的做法无异于“竭泽而渔”，呼吁相关平台企业彻底扭转唯“流量至上”的错误思维，正视消费者合法权益，主动承担社会责任，强化平台治理，用诚信合规经营创造更大价值。接下来，上海市消保委还将对存在相关问题的其他平台进行约谈。","news_type":1},"isVote":1,"tweetType":1,"viewCount":168,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":274865270403192,"gmtCreate":1708143562466,"gmtModify":1708143567965,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"huat huat huat dragon year","listText":"huat huat huat dragon year","text":"huat huat huat dragon year","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/274865270403192","isVote":1,"tweetType":1,"viewCount":422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379850043,"gmtCreate":1618718288382,"gmtModify":1704714294937,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":1,"link":"https://ttm.financial/post/379850043","repostId":"1145242426","repostType":4,"repost":{"id":"1145242426","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1618579826,"share":"https://ttm.financial/m/news/1145242426?lang=&edition=fundamental","pubTime":"2021-04-16 21:30","market":"us","language":"en","title":"U.S. stocks gained in Friday open. Blockchain stocks fell","url":"https://stock-news.laohu8.com/highlight/detail?id=1145242426","media":"Tiger Newspress","summary":"(April 16) U.S. stocks shot higher at the open Friday, aiming for fresh records, as economic reports","content":"<p>(April 16)&nbsp;U.S. stocks shot higher at the open Friday, aiming for fresh records, as economic reports and corporate results remained strong. S&amp;P 500 edges higher to another all-time high, on pace for 4th straight positive week.</p><p>The Dow Jones Industrial Average added 157 points, 0.5%, to open near 34,193, while the S&amp;P 500 added 15 points, 0.4%, starting trading near 4,185. Both indexes clinched record closes Thursday. The Nasdaq Composite index,&nbsp; meanwhile, ticked up 0.1%, about 15 points, to trade near 14,053.</p><p>The pace of residential construction quickened in March, according to the most recent housing starts report and Morgan Stanley said profit doubled in the first quarter, topping analyst expectations.</p><p>Bitcoin slides,&nbsp;Blockchain stocks fell.&nbsp;</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/86da6884447eed1c7e8c7b86db77eb7f\" tg-width=\"313\" tg-height=\"361\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 09:37</span></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks gained in Friday open. Blockchain stocks fell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks gained in Friday open. Blockchain stocks fell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-16 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(April 16)&nbsp;U.S. stocks shot higher at the open Friday, aiming for fresh records, as economic reports and corporate results remained strong. S&amp;P 500 edges higher to another all-time high, on pace for 4th straight positive week.</p><p>The Dow Jones Industrial Average added 157 points, 0.5%, to open near 34,193, while the S&amp;P 500 added 15 points, 0.4%, starting trading near 4,185. Both indexes clinched record closes Thursday. The Nasdaq Composite index,&nbsp; meanwhile, ticked up 0.1%, about 15 points, to trade near 14,053.</p><p>The pace of residential construction quickened in March, according to the most recent housing starts report and Morgan Stanley said profit doubled in the first quarter, topping analyst expectations.</p><p>Bitcoin slides,&nbsp;Blockchain stocks fell.&nbsp;</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/86da6884447eed1c7e8c7b86db77eb7f\" tg-width=\"313\" tg-height=\"361\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 09:37</span></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145242426","content_text":"(April 16) U.S. stocks shot higher at the open Friday, aiming for fresh records, as economic reports and corporate results remained strong. S&P 500 edges higher to another all-time high, on pace for 4th straight positive week.The Dow Jones Industrial Average added 157 points, 0.5%, to open near 34,193, while the S&P 500 added 15 points, 0.4%, starting trading near 4,185. Both indexes clinched record closes Thursday. The Nasdaq Composite index,  meanwhile, ticked up 0.1%, about 15 points, to trade near 14,053.The pace of residential construction quickened in March, according to the most recent housing starts report and Morgan Stanley said profit doubled in the first quarter, topping analyst expectations.Bitcoin slides, Blockchain stocks fell. *Source From Tiger Trade, EST 09:37","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":342089983,"gmtCreate":1618127769942,"gmtModify":1704706855513,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CELC\">$Celcuity Inc(CELC)$</a>great","listText":"<a href=\"https://laohu8.com/S/CELC\">$Celcuity Inc(CELC)$</a>great","text":"$Celcuity Inc(CELC)$great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/342089983","isVote":1,"tweetType":1,"viewCount":398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":340307576,"gmtCreate":1617336295095,"gmtModify":1704698942803,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/340307576","repostId":"1119793308","repostType":4,"isVote":1,"tweetType":1,"viewCount":71,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":346882936,"gmtCreate":1618021116325,"gmtModify":1704706047893,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/346882936","repostId":"2126038125","repostType":4,"repost":{"id":"2126038125","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1617981432,"share":"https://ttm.financial/m/news/2126038125?lang=&edition=fundamental","pubTime":"2021-04-09 23:17","market":"us","language":"en","title":"EU seeks new contract with Pfizer/BioNTech for up to 1.8 billion vaccines from 2022 -EU source","url":"https://stock-news.laohu8.com/highlight/detail?id=2126038125","media":"Reuters","summary":"BRUSSELS, April 9 (Reuters) - The European Commission is seeking EU governments’ approval to launch ","content":"<p>BRUSSELS, April 9 (Reuters) - The European Commission is seeking EU governments’ approval to launch talks with Pfizer and BioNTech for the purchase of up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, an EU official told Reuters.</p>\n<p>Earlier on Friday, German daily Die Welt reported that the Commission was shortly to sign contracts to buy up to 1.8 billion doses, but did not say with which company.</p>\n<p>The EU official, who asked not to be named because the matter is confidential, said the EU executive had already decided to approach Pfizer-BioNTech and that EU governments backed the plan, though there was not yet a definitive approval.</p>\n<p>A Commission spokesman confirmed plans to buy the additional doses, of which half would be optional.</p>\n<p>He also confirmed that the EU executive had already identified one supplier, a manufacturer of mRNA vaccines, but declined to comment on which company would be approached to negotiate the contract.</p>\n<p>“If provided the opportunity Pfizer and BioNTech are prepared to supply Europe with hundreds of millions of doses of COVID vaccines in 2022 and 2023 produced in our manufacturing facilities in Europe,” a Pfizer spokesman said.</p>\n<p>The two companies have the capacity to produce more than 3 billion doses of vaccine in 2022, he added.</p>\n<p>Pfizer-BioNTech and Moderna are already supplying the EU with mRNA vaccines and German biotech firm CureVac is seeking EU approval for its mRNA shot.</p>\n<p>The vaccines would be delivered under monthly timetables and with clauses obliging the supplier to deliver, the EU official said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU seeks new contract with Pfizer/BioNTech for up to 1.8 billion vaccines from 2022 -EU source</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU seeks new contract with Pfizer/BioNTech for up to 1.8 billion vaccines from 2022 -EU source\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-09 23:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BRUSSELS, April 9 (Reuters) - The European Commission is seeking EU governments’ approval to launch talks with Pfizer and BioNTech for the purchase of up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, an EU official told Reuters.</p>\n<p>Earlier on Friday, German daily Die Welt reported that the Commission was shortly to sign contracts to buy up to 1.8 billion doses, but did not say with which company.</p>\n<p>The EU official, who asked not to be named because the matter is confidential, said the EU executive had already decided to approach Pfizer-BioNTech and that EU governments backed the plan, though there was not yet a definitive approval.</p>\n<p>A Commission spokesman confirmed plans to buy the additional doses, of which half would be optional.</p>\n<p>He also confirmed that the EU executive had already identified one supplier, a manufacturer of mRNA vaccines, but declined to comment on which company would be approached to negotiate the contract.</p>\n<p>“If provided the opportunity Pfizer and BioNTech are prepared to supply Europe with hundreds of millions of doses of COVID vaccines in 2022 and 2023 produced in our manufacturing facilities in Europe,” a Pfizer spokesman said.</p>\n<p>The two companies have the capacity to produce more than 3 billion doses of vaccine in 2022, he added.</p>\n<p>Pfizer-BioNTech and Moderna are already supplying the EU with mRNA vaccines and German biotech firm CureVac is seeking EU approval for its mRNA shot.</p>\n<p>The vaccines would be delivered under monthly timetables and with clauses obliging the supplier to deliver, the EU official said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2126038125","content_text":"BRUSSELS, April 9 (Reuters) - The European Commission is seeking EU governments’ approval to launch talks with Pfizer and BioNTech for the purchase of up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, an EU official told Reuters.\nEarlier on Friday, German daily Die Welt reported that the Commission was shortly to sign contracts to buy up to 1.8 billion doses, but did not say with which company.\nThe EU official, who asked not to be named because the matter is confidential, said the EU executive had already decided to approach Pfizer-BioNTech and that EU governments backed the plan, though there was not yet a definitive approval.\nA Commission spokesman confirmed plans to buy the additional doses, of which half would be optional.\nHe also confirmed that the EU executive had already identified one supplier, a manufacturer of mRNA vaccines, but declined to comment on which company would be approached to negotiate the contract.\n“If provided the opportunity Pfizer and BioNTech are prepared to supply Europe with hundreds of millions of doses of COVID vaccines in 2022 and 2023 produced in our manufacturing facilities in Europe,” a Pfizer spokesman said.\nThe two companies have the capacity to produce more than 3 billion doses of vaccine in 2022, he added.\nPfizer-BioNTech and Moderna are already supplying the EU with mRNA vaccines and German biotech firm CureVac is seeking EU approval for its mRNA shot.\nThe vaccines would be delivered under monthly timetables and with clauses obliging the supplier to deliver, the EU official said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105928944,"gmtCreate":1620265054688,"gmtModify":1704341004005,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NMRD\">$Nemaura Medical, Inc.(NMRD)$</a>super","listText":"<a href=\"https://laohu8.com/S/NMRD\">$Nemaura Medical, Inc.(NMRD)$</a>super","text":"$Nemaura Medical, Inc.(NMRD)$super","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105928944","isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":346886355,"gmtCreate":1618021076377,"gmtModify":1704706047080,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/346886355","repostId":"1142324412","repostType":4,"repost":{"id":"1142324412","pubTimestamp":1617982207,"share":"https://ttm.financial/m/news/1142324412?lang=&edition=fundamental","pubTime":"2021-04-09 23:30","market":"us","language":"en","title":"XPeng Inc.: A Reawakening","url":"https://stock-news.laohu8.com/highlight/detail?id=1142324412","media":"seekingalpha","summary":"Valuation is middling but not overvalued like in the past.Recent announcement of capacity expansion in Wuhan lends better operational and sales visibility.Company could breakeven and finally reach positive profits soon; major improvements seen in operating margins.Feared chip shortage  was not a disaster, deliveries are still strong.Government support, China's creation of an EV ecosystem.XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese go","content":"<p><b>Summary</b></p>\n<ul>\n <li>Valuation is middling but not overvalued like in the past.</li>\n <li>Recent announcement of capacity expansion in Wuhan lends better operational and sales visibility.</li>\n <li>Company could breakeven and finally reach positive profits soon; major improvements seen in operating margins.</li>\n <li>Feared chip shortage (i.e. supply disruption) was not a disaster, deliveries are still strong.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e0f3343d69719839f9b8f1d337c3984\" tg-width=\"1536\" tg-height=\"1024\"><span>Photo by Robert Way/iStock Editorial via Getty Images</span></p>\n<p><b>Introduction</b></p>\n<p>The stock price of&nbsp;XPEV&nbsp;has been converging with the performance of the S&amp;P 500 since March 2021, as compared to its massive outperformance in 4Q2020. This could be view positively or negatively. On the bright side, this suggests that price performance would become more predictable with lower volatility, indicative of a broadening consensus on the fundamental prospects of the company. On the other hand, traders may be disappointed its lack of momentum. Therefore, this is probably a good time to stop viewing XPEV as purely a trade, but re-analyze its merits as a fundamentally-driven investment.</p>\n<p><i>The frenetic performance of XPEV has calmed down in recent weeks, allowing its one year performance to track the S&amp;P 500 more closely</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9f04001d604ecc7892ef3a76c498578b\" tg-width=\"640\" tg-height=\"236\"><span>Source: SeekingAlpha</span></p>\n<p><i>XPEV's G3 Super Long Range Smart SUV</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/68446a741f9f97afc10f2149c4e13e13\" tg-width=\"640\" tg-height=\"388\"><span>Source: XPeng Motors (G3、P7) Intelligent electric car with Internet DNA</span></p>\n<p><b>Industry and commercial positives</b></p>\n<p>Optimism on EVs and&nbsp;strong industry growth&nbsp;rates are common knowledge by now. The following points suggest specific positives for XPEV that remain intact despite relatively ebbing momentum on the stock's price (as compared to 4Q2020):</p>\n<ol>\n <li><b>Deliveries met despite fears on chip shortage.</b>While the stock's price momentum appears to have ebbed, recent news continues to remain positive. At an industry level, Chinese vehicle manufacturers XPEV andNIOmanaged to manufacture the expected numbers of vehicle deliveries, despite much feared chip shortages.XPEV chalked&nbsp;in record quarterly deliveries of 13,340 EVs in Q1 2021, +487% over the year and +130% over the month in March.NIO delivered&nbsp;20,060 +423% over the year while Q1 deliveries rose 15.6% to 20,060. The challenge these EV manufacturers face now is not so much the ability to deliver on its numbers, but on being able to meet high expectations for the stock price to gain further traction.</li>\n <li><b>Government support, China's creation of an EV ecosystem.</b>XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese government's push to develop this part of its industry. XPEV has entered into an agreement with the city of Wuhan to build a factory with a capacity of 100,000 EV units. This is a very significant piece of news, considering its deliveries of just 5,102 in March 2021. Annualizing this number, the new capacity will be more than the whole of XPEV's total historical annual production. This news is interesting and significant since it was just released this week, suggesting it may have yet to be factored into analysts' forecast numbers. This is made more important as XPEV has always been considered a laggard in production capabilities to its larger cousin NIO. General Chinese government support for the EV ecosystem is strong, and the new facility in Wuhan echoes earlier provincial government financial support ($77m) in Guangdong. The reality is, for EVs to gain traction, government willingness to support infrastructure initiatives are highly important (e.g. permits for charging stations, creating incentives to convert from old polluting vehicles to green vehicles, etc.). With China's tradition of central planning, the EV ecosystem is placed on the right footing.</li>\n <li><b>Listing in Hong Kong adds to investor base and liquidity.</b>Going forward,XPEV,NIO, and&nbsp;LI&nbsp;intend tolistin Hong Kong this year. This is a strategic move, and makes the valuation of these companies less susceptible by US political bashing (e.g. the threat of being de-listed) should it occur, since it reflects a wider geographical base. The valuations of these companies may even get a boost given greater global liquidity due to added trading in the Asian time zone.</li>\n</ol>\n<p>Of note, in late March, XPEV held an&nbsp;autonomous driving expedition&nbsp;covering eight cities in China and 3,675 kilometers. The exercise was successful, as minimal human intervention was needed during the expedition and adds another brownie point to XPEV's research and development efforts, placing XPEV on the&nbsp;competitive landscape&nbsp;against rivals such as TSLA and NIO on autonomous driving. Apparently, XPEV's autonomous driving results&nbsp;performed better&nbsp;than TSLA's with fewer human interventions per 100km and better navigation in complex situations.</p>\n<p><b>XPEV's improving financials</b></p>\n<p>Now that we have several quarters of financial data on XPEV, it is worth reviewing how its metrics have been performing. Firstly, market expectations aside, deliveries have been very good as abovementioned, and this is flowing through to revenue numbers. As shown in the below table, growth has been very strong, and revenues are expected to more than double in 2021 and continue to double in 2022. Such growth rates place XPEV at the top end of manufacturing firms, as expected of the fast-growing EV market.</p>\n<p>Another point to note is the improvement in operating margins. As with any \"new tech\" company, initial investments would cause hugely negative operating margins in the beginning. What's important is the company's ability to improve margins and reduce costs over time. In this respect, XPEV has done a good job, with operating margins improving sequentially each quarter. Of note, operating margins started to see major improvements between the Jun-2020 (-142%) and Dec-2020 (-39%) quarters as shown in the table below. Given this trend, the company is likely to breakeven and register positive profits soon, which could be a catalytic re-rating for XPEV. When we pair this analysis with the stock price, it appears that XPEV's recently soft stock price performance is not justified.</p>\n<p>Meanwhile, the balance sheet is expected to remain strong. Equity to total liabilities &amp; equity is 23% as at Dec-2020. As abovementioned, further capital raises with a forthcoming Hong Kong listing will add to XPEV's cash buffer.</p>\n<p><i>XPEV's performance improvement in both revenue and operating margin trends appear to have been ignored by the market due to recent the broad market capitulation</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f8258dce0cc10e8118a23afce7655bed\" tg-width=\"726\" tg-height=\"737\"><span>*EST = estimate by analysts' consensus from SeekingAlpha</span></p>\n<p><b>XPEV's valuation: somewhere in the middle</b></p>\n<p>XPEV's stock price has done well over the last 6 months versus peers. On a TTM P/S, XPEV is near the middle although its FWD P/S is trading at a premium. However, there could be a general re-rating of the P/S of the sector if the Chinese EV manufacturers reach breakeven in 2021 and record positive profits (our base case belief, given the prevailing trend in XPEV's improving operating margins). This will then allow better price discovery when the companies can then be valued on their P/E ratios.</p>\n<img src=\"https://static.tigerbbs.com/fa975ce545e950a20f809bcc7f698ef6\" tg-width=\"911\" tg-height=\"594\">\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p><b>Conclusion and Risks</b></p>\n<p>XPEV's stock price may benefit from two key catalysts: (1) expansion of manufacturing facility in Wuhan, which will concretely raise visibility of revenue growth which is expected to double; (2) a valuation regime change as it progresses from a loss making company to a profitable one, expected by this year. Furthermore, it is worth noting that the valuation is not lofty as compared to price levels in 4Q2020, having fallen over the last couple of months.</p>\n<p>Competition may exist and remain intense, but given the large size of China's market and that there are only a couple of notable players (i.e. NIO, LI), the market remains largely an oligopoly which allows XPEV to retain pricing power.</p>\n<p>Much feared risks of execution in the past appear to have materialized but not in a big way, i.e. the previously expected chip shortage. Given the progression to a post-COVID economy, supply chain links should improve and reduce similar risks in the future.</p>\n<p>On a standalone basis, XPEV's prospects appear bright, and now the key hurdle is whether the NASDAQ will find momentum and exceed previous highs. The base case for this should lean towards the positive as the market is merely in the first year of the economic recovery after the pandemic. Recent price consolidation appears to have created a technical setup for a reawakening of price momentum as consumer activity revives post-pandemic.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng Inc.: A Reawakening</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng Inc.: A Reawakening\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4418326-xpeng-inc-reawakening><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nValuation is middling but not overvalued like in the past.\nRecent announcement of capacity expansion in Wuhan lends better operational and sales visibility.\nCompany could breakeven and ...</p>\n\n<a href=\"https://seekingalpha.com/article/4418326-xpeng-inc-reawakening\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车"},"source_url":"https://seekingalpha.com/article/4418326-xpeng-inc-reawakening","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1142324412","content_text":"Summary\n\nValuation is middling but not overvalued like in the past.\nRecent announcement of capacity expansion in Wuhan lends better operational and sales visibility.\nCompany could breakeven and finally reach positive profits soon; major improvements seen in operating margins.\nFeared chip shortage (i.e. supply disruption) was not a disaster, deliveries are still strong.\n\nPhoto by Robert Way/iStock Editorial via Getty Images\nIntroduction\nThe stock price of XPEV has been converging with the performance of the S&P 500 since March 2021, as compared to its massive outperformance in 4Q2020. This could be view positively or negatively. On the bright side, this suggests that price performance would become more predictable with lower volatility, indicative of a broadening consensus on the fundamental prospects of the company. On the other hand, traders may be disappointed its lack of momentum. Therefore, this is probably a good time to stop viewing XPEV as purely a trade, but re-analyze its merits as a fundamentally-driven investment.\nThe frenetic performance of XPEV has calmed down in recent weeks, allowing its one year performance to track the S&P 500 more closely\nSource: SeekingAlpha\nXPEV's G3 Super Long Range Smart SUV\nSource: XPeng Motors (G3、P7) Intelligent electric car with Internet DNA\nIndustry and commercial positives\nOptimism on EVs and strong industry growth rates are common knowledge by now. The following points suggest specific positives for XPEV that remain intact despite relatively ebbing momentum on the stock's price (as compared to 4Q2020):\n\nDeliveries met despite fears on chip shortage.While the stock's price momentum appears to have ebbed, recent news continues to remain positive. At an industry level, Chinese vehicle manufacturers XPEV andNIOmanaged to manufacture the expected numbers of vehicle deliveries, despite much feared chip shortages.XPEV chalked in record quarterly deliveries of 13,340 EVs in Q1 2021, +487% over the year and +130% over the month in March.NIO delivered 20,060 +423% over the year while Q1 deliveries rose 15.6% to 20,060. The challenge these EV manufacturers face now is not so much the ability to deliver on its numbers, but on being able to meet high expectations for the stock price to gain further traction.\nGovernment support, China's creation of an EV ecosystem.XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese government's push to develop this part of its industry. XPEV has entered into an agreement with the city of Wuhan to build a factory with a capacity of 100,000 EV units. This is a very significant piece of news, considering its deliveries of just 5,102 in March 2021. Annualizing this number, the new capacity will be more than the whole of XPEV's total historical annual production. This news is interesting and significant since it was just released this week, suggesting it may have yet to be factored into analysts' forecast numbers. This is made more important as XPEV has always been considered a laggard in production capabilities to its larger cousin NIO. General Chinese government support for the EV ecosystem is strong, and the new facility in Wuhan echoes earlier provincial government financial support ($77m) in Guangdong. The reality is, for EVs to gain traction, government willingness to support infrastructure initiatives are highly important (e.g. permits for charging stations, creating incentives to convert from old polluting vehicles to green vehicles, etc.). With China's tradition of central planning, the EV ecosystem is placed on the right footing.\nListing in Hong Kong adds to investor base and liquidity.Going forward,XPEV,NIO, and LI intend tolistin Hong Kong this year. This is a strategic move, and makes the valuation of these companies less susceptible by US political bashing (e.g. the threat of being de-listed) should it occur, since it reflects a wider geographical base. The valuations of these companies may even get a boost given greater global liquidity due to added trading in the Asian time zone.\n\nOf note, in late March, XPEV held an autonomous driving expedition covering eight cities in China and 3,675 kilometers. The exercise was successful, as minimal human intervention was needed during the expedition and adds another brownie point to XPEV's research and development efforts, placing XPEV on the competitive landscape against rivals such as TSLA and NIO on autonomous driving. Apparently, XPEV's autonomous driving results performed better than TSLA's with fewer human interventions per 100km and better navigation in complex situations.\nXPEV's improving financials\nNow that we have several quarters of financial data on XPEV, it is worth reviewing how its metrics have been performing. Firstly, market expectations aside, deliveries have been very good as abovementioned, and this is flowing through to revenue numbers. As shown in the below table, growth has been very strong, and revenues are expected to more than double in 2021 and continue to double in 2022. Such growth rates place XPEV at the top end of manufacturing firms, as expected of the fast-growing EV market.\nAnother point to note is the improvement in operating margins. As with any \"new tech\" company, initial investments would cause hugely negative operating margins in the beginning. What's important is the company's ability to improve margins and reduce costs over time. In this respect, XPEV has done a good job, with operating margins improving sequentially each quarter. Of note, operating margins started to see major improvements between the Jun-2020 (-142%) and Dec-2020 (-39%) quarters as shown in the table below. Given this trend, the company is likely to breakeven and register positive profits soon, which could be a catalytic re-rating for XPEV. When we pair this analysis with the stock price, it appears that XPEV's recently soft stock price performance is not justified.\nMeanwhile, the balance sheet is expected to remain strong. Equity to total liabilities & equity is 23% as at Dec-2020. As abovementioned, further capital raises with a forthcoming Hong Kong listing will add to XPEV's cash buffer.\nXPEV's performance improvement in both revenue and operating margin trends appear to have been ignored by the market due to recent the broad market capitulation\n*EST = estimate by analysts' consensus from SeekingAlpha\nXPEV's valuation: somewhere in the middle\nXPEV's stock price has done well over the last 6 months versus peers. On a TTM P/S, XPEV is near the middle although its FWD P/S is trading at a premium. However, there could be a general re-rating of the P/S of the sector if the Chinese EV manufacturers reach breakeven in 2021 and record positive profits (our base case belief, given the prevailing trend in XPEV's improving operating margins). This will then allow better price discovery when the companies can then be valued on their P/E ratios.\n\n\n\n\n\n\nConclusion and Risks\nXPEV's stock price may benefit from two key catalysts: (1) expansion of manufacturing facility in Wuhan, which will concretely raise visibility of revenue growth which is expected to double; (2) a valuation regime change as it progresses from a loss making company to a profitable one, expected by this year. Furthermore, it is worth noting that the valuation is not lofty as compared to price levels in 4Q2020, having fallen over the last couple of months.\nCompetition may exist and remain intense, but given the large size of China's market and that there are only a couple of notable players (i.e. NIO, LI), the market remains largely an oligopoly which allows XPEV to retain pricing power.\nMuch feared risks of execution in the past appear to have materialized but not in a big way, i.e. the previously expected chip shortage. Given the progression to a post-COVID economy, supply chain links should improve and reduce similar risks in the future.\nOn a standalone basis, XPEV's prospects appear bright, and now the key hurdle is whether the NASDAQ will find momentum and exceed previous highs. The base case for this should lean towards the positive as the market is merely in the first year of the economic recovery after the pandemic. Recent price consolidation appears to have created a technical setup for a reawakening of price momentum as consumer activity revives post-pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":58,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":196618131,"gmtCreate":1621047820823,"gmtModify":1704352424443,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EJH\">$E-home Service(EJH)$</a>wa, what is this","listText":"<a href=\"https://laohu8.com/S/EJH\">$E-home Service(EJH)$</a>wa, what is this","text":"$E-home Service(EJH)$wa, what is this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/196618131","isVote":1,"tweetType":1,"viewCount":73,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376310569,"gmtCreate":1619088731351,"gmtModify":1704719439158,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/376310569","repostId":"1147263213","repostType":4,"repost":{"id":"1147263213","pubTimestamp":1619075516,"share":"https://ttm.financial/m/news/1147263213?lang=&edition=fundamental","pubTime":"2021-04-22 15:11","market":"us","language":"en","title":"Intel Reports Earnings Thursday. Here’s What to Know.","url":"https://stock-news.laohu8.com/highlight/detail?id=1147263213","media":"Barrons","summary":"Weeks after Intel installed chief executive Pat Gelsinger and its rollout of a $20 billion plan to expand its manufacturing operations, the company is set to report its earnings.As part of the plan, Intel said it would once again license its x86 chip designs to other companies, and create a foundry services unit that would produce chips for third parties interested in paying Intel to fabricate semiconductors.Intel didn’t issue precise new financial guidance for the first quarter, but said it exp","content":"<p>Weeks after Intel installed chief executive Pat Gelsinger and its rollout of a $20 billion plan to expand its manufacturing operations, the company is set to report its earnings.</p>\n<p>Investors already have a solid idea of what the report, due after the close of trading on Thursday, will bring. When Gelsinger unveiled the company’s plans for the future in late March,Intel (ticker: INTC) said it expected full-year earnings of $4 a share from revenue of $76.5 billion. Including various adjustments, such as those related to Intel’s sale of its flash-memory business in 2020, EPS is likely to be $4.55, while revenue is expected to be $72 billion, the company said.</p>\n<p>As part of the plan, Intel said it would once again license its x86 chip designs to other companies, and create a foundry services unit that would produce chips for third parties interested in paying Intel to fabricate semiconductors.</p>\n<p>Intel didn’t issue precise new financial guidance for the first quarter, but said it expected results better than its prior forecast. Previously, Intel said it expected adjusted first-quarter earnings of $1.10 a share and revenue of $17.5 billion. The consensus forecast is for adjusted earnings of $1.15 a share from revenue of $17.74 billion.</p>\n<p>Susquehanna Financial Group analyst Christopher Rolland,who called the company’s full-year guidance “underwhelming,” said he is expecting investors to focus on Gelsinger’s long-term plans for the company, and to look for more details about Intel’s next generation chip-making technology. According to the analyst’s data sources, notebook sales were strong in the first quarter, but it is less clear what’s coming through the rest of the year.</p>\n<p>Analysts predict that Intel’s client computing segment, which includes notebook sales, will report first-quarter revenue of $10.02 billion. That is the company’s largest segment, followed by the data center operation, which is expected to report revenue of $5.84 billion.</p>\n<p>Despite Intel’s decision to double down on its manufacturing capabilities, BMO Capital Markets analyst Ambrish Srivastava wrote in a client note Monday that he isn’t expecting executives to offer details about its goals, and their effect on Intel’s financial performance.</p>\n<p>Still, Srivastava said, investors should watch closely for commentary about the impact to the company’s capital spending, profit, and free cash flow, among other things.</p>\n<p>Intel’s report arrives amid a global shortage of semiconductors that is hurting production of goods ranging from appliances to cars and videogame consoles. Gelsinger has previously told&nbsp;<i>Barron’s</i> that he expects the chip shortage to last two years.</p>\n<p>Of the analysts that cover Intel, 43% rate shares at Buy, 34% have Hold ratings, and 23% rate the stock at Sell. The average target for the stock price is $68.71, which implies a return of 8.6%.</p>\n<p>Intel stock advanced 1.6% to $63.70 in Wednesday trading. Shares in the chip maker have gained 12% in the past year, while the PHLX Semiconductor index, or Sox, has doubled.</p>\n<p>Rolland pointed out that since Intel’s most recent quarterly report, its stock has gained 14%, while the Sox rose 5.8%. The analyst said that outperformance may indicate that expectations for the earnings are high, a potential negative for the stock.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Reports Earnings Thursday. Here’s What to Know.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Reports Earnings Thursday. Here’s What to Know.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-22 15:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/intel-reports-earnings-thursday-heres-what-to-know-51619037330?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Weeks after Intel installed chief executive Pat Gelsinger and its rollout of a $20 billion plan to expand its manufacturing operations, the company is set to report its earnings.\nInvestors already ...</p>\n\n<a href=\"https://www.barrons.com/articles/intel-reports-earnings-thursday-heres-what-to-know-51619037330?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"source_url":"https://www.barrons.com/articles/intel-reports-earnings-thursday-heres-what-to-know-51619037330?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147263213","content_text":"Weeks after Intel installed chief executive Pat Gelsinger and its rollout of a $20 billion plan to expand its manufacturing operations, the company is set to report its earnings.\nInvestors already have a solid idea of what the report, due after the close of trading on Thursday, will bring. When Gelsinger unveiled the company’s plans for the future in late March,Intel (ticker: INTC) said it expected full-year earnings of $4 a share from revenue of $76.5 billion. Including various adjustments, such as those related to Intel’s sale of its flash-memory business in 2020, EPS is likely to be $4.55, while revenue is expected to be $72 billion, the company said.\nAs part of the plan, Intel said it would once again license its x86 chip designs to other companies, and create a foundry services unit that would produce chips for third parties interested in paying Intel to fabricate semiconductors.\nIntel didn’t issue precise new financial guidance for the first quarter, but said it expected results better than its prior forecast. Previously, Intel said it expected adjusted first-quarter earnings of $1.10 a share and revenue of $17.5 billion. The consensus forecast is for adjusted earnings of $1.15 a share from revenue of $17.74 billion.\nSusquehanna Financial Group analyst Christopher Rolland,who called the company’s full-year guidance “underwhelming,” said he is expecting investors to focus on Gelsinger’s long-term plans for the company, and to look for more details about Intel’s next generation chip-making technology. According to the analyst’s data sources, notebook sales were strong in the first quarter, but it is less clear what’s coming through the rest of the year.\nAnalysts predict that Intel’s client computing segment, which includes notebook sales, will report first-quarter revenue of $10.02 billion. That is the company’s largest segment, followed by the data center operation, which is expected to report revenue of $5.84 billion.\nDespite Intel’s decision to double down on its manufacturing capabilities, BMO Capital Markets analyst Ambrish Srivastava wrote in a client note Monday that he isn’t expecting executives to offer details about its goals, and their effect on Intel’s financial performance.\nStill, Srivastava said, investors should watch closely for commentary about the impact to the company’s capital spending, profit, and free cash flow, among other things.\nIntel’s report arrives amid a global shortage of semiconductors that is hurting production of goods ranging from appliances to cars and videogame consoles. Gelsinger has previously told Barron’s that he expects the chip shortage to last two years.\nOf the analysts that cover Intel, 43% rate shares at Buy, 34% have Hold ratings, and 23% rate the stock at Sell. The average target for the stock price is $68.71, which implies a return of 8.6%.\nIntel stock advanced 1.6% to $63.70 in Wednesday trading. Shares in the chip maker have gained 12% in the past year, while the PHLX Semiconductor index, or Sox, has doubled.\nRolland pointed out that since Intel’s most recent quarterly report, its stock has gained 14%, while the Sox rose 5.8%. The analyst said that outperformance may indicate that expectations for the earnings are high, a potential negative for the stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":209,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9060537946,"gmtCreate":1651163945201,"gmtModify":1676534862230,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9060537946","repostId":"2230408224","repostType":4,"repost":{"id":"2230408224","pubTimestamp":1651157900,"share":"https://ttm.financial/m/news/2230408224?lang=&edition=fundamental","pubTime":"2022-04-28 22:58","market":"us","language":"en","title":"Why Teladoc Health's Latest Earnings Call Was So Disappointing","url":"https://stock-news.laohu8.com/highlight/detail?id=2230408224","media":"Motley Fool","summary":"An enormous write-down on its chronic-care business is just part of the problem.","content":"<html><head></head><body><p>Quick: Somebody call a virtual doctor! The stock market just pushed America&#39;s leading telehealth business down a flight of stairs.</p><p>Shares of <b>Teladoc Health</b> fell hard after U.S. stock markets closed on Wednesday in response to a dismal first-quarter earnings call. The company was able to report total revenue that soared 25% year over year, but the market is responding to signs of trouble that aren&#39;t apparent until you look past the headline numbers.</p><p>Here&#39;s why investment bank analysts quickly lined up to downgrade the already embattled telehealth stock.</p><h2>A chronic disaster</h2><p>Using smartphones to connect patients with doctors is a minor challenge that at least a dozen of Teladoc&#39;s competitors can handle. With this fear of commoditization in mind, Teladoc Health boldly acquired a chronic-care management business called Livongo Health for $18.5 billion in 2020.</p><p>Just before the acquisition, Livongo was growing by leaps and bounds. On Sept. 30, 2020, Livongo for Diabetes had 442,000 members, which was 113% more than it had a year earlier.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F676616%2Fchronic-care-membership-following-the-acquisition-of-livongo.png&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"432\" width=\"100%\" height=\"auto\"/><span>Data source: Teladoc Health. Chart by author.</span></p><p>Livongo had already begun expanding from its flagship diabetes service to blood pressure management and weight loss at the time of the acquisition. Despite having a lot more resources to work with than Livongo did, Teladoc hasn&#39;t been able to repeat Livongo&#39;s success. In fact, chronic-care membership has slowed down so much that the company had to record a whopping $6.6 billion impairment charge related to the Livongo acquisition.</p><h2>BetterHelp needs help</h2><p>Teladoc Health&#39;s chronic-care numbers have been disappointing for over a year. But BetterHelp, its mental health segment, was until recently making big gains. Unfortunately, the company is losing ground to well-funded competitors that keep entering the market.</p><p>For example, <b>Talkspace</b> went public in a $1.4 billion deal with a special purpose acquisition company (SPAC) last year.</p><p>When reporting first-quarter results, Teladoc Health walked back the forward-looking guidance it provided three months earlier. Instead of revenue rising to a range between $2.55 billion and $2.65 billion, the company told investors to expect between $2.4 billion and $2.5 billion in top-line sales. According to management, investing in heavy advertising for BetterHelp has been delivering lower returns than it used to. Specifically, the company complained about increasing competition for keywords associated with online therapy.</p><h2>More trouble ahead</h2><p>Teladoc Health is the largest independent telehealth business in America, but it&#39;s competing with some deep-pocketed giants of the healthcare-benefits management industry that want their members to see the physicians they employ.</p><p>For example, <b>CVS Health</b> acquired Aetna a few years ago, and it also operates MinuteClinics in many of its pharmacies that also offer virtual visits. CVS Health would never say so in so many words, but it has a lot to gain when Aetna members visit physicians employed by a CVS MinuteClinic versus Teladoc Health.</p><p>Cash flow generated by CVS Health&#39;s highly integrated operations reached a whopping $18.3 billion last year, and the company expects between $12.5 billion and $13 billion this year. In stark contrast, cash from Teladoc Health&#39;s operations came in below $200 million last year and slid back into negative territory in the first quarter of 2022.</p><p>Teladoc Health may be the largest pure-play business in the telehealth industry, but we still don&#39;t know if it can compete with giant healthcare benefits managers and a slew of smaller upstarts at the same time. It&#39;s probably a good idea to watch the company&#39;s story play out from a safe distance until we see signs it can compete in a rapidly shifting market for telehealth services.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Teladoc Health's Latest Earnings Call Was So Disappointing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Teladoc Health's Latest Earnings Call Was So Disappointing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-28 22:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/28/why-teladoc-healths-latest-earnings-call-was-so-di/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quick: Somebody call a virtual doctor! The stock market just pushed America's leading telehealth business down a flight of stairs.Shares of Teladoc Health fell hard after U.S. stock markets closed on ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/28/why-teladoc-healths-latest-earnings-call-was-so-di/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/04/28/why-teladoc-healths-latest-earnings-call-was-so-di/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2230408224","content_text":"Quick: Somebody call a virtual doctor! The stock market just pushed America's leading telehealth business down a flight of stairs.Shares of Teladoc Health fell hard after U.S. stock markets closed on Wednesday in response to a dismal first-quarter earnings call. The company was able to report total revenue that soared 25% year over year, but the market is responding to signs of trouble that aren't apparent until you look past the headline numbers.Here's why investment bank analysts quickly lined up to downgrade the already embattled telehealth stock.A chronic disasterUsing smartphones to connect patients with doctors is a minor challenge that at least a dozen of Teladoc's competitors can handle. With this fear of commoditization in mind, Teladoc Health boldly acquired a chronic-care management business called Livongo Health for $18.5 billion in 2020.Just before the acquisition, Livongo was growing by leaps and bounds. On Sept. 30, 2020, Livongo for Diabetes had 442,000 members, which was 113% more than it had a year earlier.Data source: Teladoc Health. Chart by author.Livongo had already begun expanding from its flagship diabetes service to blood pressure management and weight loss at the time of the acquisition. Despite having a lot more resources to work with than Livongo did, Teladoc hasn't been able to repeat Livongo's success. In fact, chronic-care membership has slowed down so much that the company had to record a whopping $6.6 billion impairment charge related to the Livongo acquisition.BetterHelp needs helpTeladoc Health's chronic-care numbers have been disappointing for over a year. But BetterHelp, its mental health segment, was until recently making big gains. Unfortunately, the company is losing ground to well-funded competitors that keep entering the market.For example, Talkspace went public in a $1.4 billion deal with a special purpose acquisition company (SPAC) last year.When reporting first-quarter results, Teladoc Health walked back the forward-looking guidance it provided three months earlier. Instead of revenue rising to a range between $2.55 billion and $2.65 billion, the company told investors to expect between $2.4 billion and $2.5 billion in top-line sales. According to management, investing in heavy advertising for BetterHelp has been delivering lower returns than it used to. Specifically, the company complained about increasing competition for keywords associated with online therapy.More trouble aheadTeladoc Health is the largest independent telehealth business in America, but it's competing with some deep-pocketed giants of the healthcare-benefits management industry that want their members to see the physicians they employ.For example, CVS Health acquired Aetna a few years ago, and it also operates MinuteClinics in many of its pharmacies that also offer virtual visits. CVS Health would never say so in so many words, but it has a lot to gain when Aetna members visit physicians employed by a CVS MinuteClinic versus Teladoc Health.Cash flow generated by CVS Health's highly integrated operations reached a whopping $18.3 billion last year, and the company expects between $12.5 billion and $13 billion this year. In stark contrast, cash from Teladoc Health's operations came in below $200 million last year and slid back into negative territory in the first quarter of 2022.Teladoc Health may be the largest pure-play business in the telehealth industry, but we still don't know if it can compete with giant healthcare benefits managers and a slew of smaller upstarts at the same time. It's probably a good idea to watch the company's story play out from a safe distance until we see signs it can compete in a rapidly shifting market for telehealth services.","news_type":1},"isVote":1,"tweetType":1,"viewCount":671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184463580,"gmtCreate":1623721931940,"gmtModify":1704209545331,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RAPT\">$RAPT Therapeutics, Inc.(RAPT)$</a>how to know this kind of share","listText":"<a href=\"https://laohu8.com/S/RAPT\">$RAPT Therapeutics, Inc.(RAPT)$</a>how to know this kind of share","text":"$RAPT Therapeutics, Inc.(RAPT)$how to know this kind of share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/184463580","isVote":1,"tweetType":1,"viewCount":934,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182651928,"gmtCreate":1623571076664,"gmtModify":1704206440636,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BZ\">$Kanzhun Limited(BZ)$</a>nice","listText":"<a href=\"https://laohu8.com/S/BZ\">$Kanzhun Limited(BZ)$</a>nice","text":"$Kanzhun Limited(BZ)$nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182651928","isVote":1,"tweetType":1,"viewCount":724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":181327655,"gmtCreate":1623375155377,"gmtModify":1704201964018,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>wah","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>wah","text":"$Orphazyme A/S(ORPH)$wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181327655","isVote":1,"tweetType":1,"viewCount":908,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3576807236070433","authorId":"3576807236070433","name":"_GOD_","avatar":"https://static.tigerbbs.com/a7926464e49b85685a50f1e80f5ff8cd","crmLevel":3,"crmLevelSwitch":1,"idStr":"3576807236070433","authorIdStr":"3576807236070433"},"content":"Wah! I made $600,000!! And sold all! I am The GOD OF STOCKS","text":"Wah! I made $600,000!! And sold all! I am The GOD OF STOCKS","html":"Wah! I made $600,000!! And sold all! I am The GOD OF STOCKS"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":115693317,"gmtCreate":1622981599039,"gmtModify":1704194042485,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>good","listText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>good","text":"$Senseonics(SENS)$good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/115693317","isVote":1,"tweetType":1,"viewCount":604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":133930853,"gmtCreate":1621680940772,"gmtModify":1704361411696,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ANVS\">$Annovis Bio, Inc.(ANVS)$</a>strong","listText":"<a href=\"https://laohu8.com/S/ANVS\">$Annovis Bio, Inc.(ANVS)$</a>strong","text":"$Annovis Bio, Inc.(ANVS)$strong","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/133930853","isVote":1,"tweetType":1,"viewCount":164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376069200,"gmtCreate":1619070779400,"gmtModify":1704719193262,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SKLZ\">$Skillz Inc(SKLZ)$</a>good","listText":"<a href=\"https://laohu8.com/S/SKLZ\">$Skillz Inc(SKLZ)$</a>good","text":"$Skillz Inc(SKLZ)$good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/376069200","isVote":1,"tweetType":1,"viewCount":117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":343299640,"gmtCreate":1617717270080,"gmtModify":1704702184718,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SJ\">$Scienjoy Holding Corp.(SJ)$</a>huge up","listText":"<a href=\"https://laohu8.com/S/SJ\">$Scienjoy Holding Corp.(SJ)$</a>huge up","text":"$Scienjoy Holding Corp.(SJ)$huge up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343299640","isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163755691,"gmtCreate":1623894465013,"gmtModify":1703822798452,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VINO\">$Gaucho Group Holdings, Inc.(VINO)$</a>wah","listText":"<a href=\"https://laohu8.com/S/VINO\">$Gaucho Group Holdings, Inc.(VINO)$</a>wah","text":"$Gaucho Group Holdings, Inc.(VINO)$wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163755691","isVote":1,"tweetType":1,"viewCount":992,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":180628529,"gmtCreate":1623202533261,"gmtModify":1704198232242,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>good","listText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>good","text":"$Clover Health Corp(CLOV)$good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180628529","isVote":1,"tweetType":1,"viewCount":764,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":137990875,"gmtCreate":1622278653597,"gmtModify":1704182646427,"author":{"id":"3576471374930041","authorId":"3576471374930041","name":"KBW","avatar":"https://static.tigerbbs.com/644c6090bfd14394469f03cf6b140b79","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576471374930041","authorIdStr":"3576471374930041"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VTNR\">$Vertex(VTNR)$</a>good","listText":"<a href=\"https://laohu8.com/S/VTNR\">$Vertex(VTNR)$</a>good","text":"$Vertex(VTNR)$good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/137990875","isVote":1,"tweetType":1,"viewCount":358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}